Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis
Science Advances · 02.05.2025 · 11 (18)
DOI: 10.1126/sciadv.adv9571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 02.05.2025. Verfasst von Zhike Chen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Myofibroblasts, Pulmonary Fibrosis, Nanoparticles, Indoles. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a life-threatening interstitial lung disease, characterized by excessive fibroblast activation and collagen deposition, leading to progressive pulmonary function decline and limited therapeutic efficacy. Here, the inhalable, myofibroblast-targeted, and pH-responsive liposomes (FL-NI) were developed for effective codelivery of nintedanib, a mainstream antifibrotic drug in clinic, and siIL11, a small interfering RNA that silences the key profibrosis cytokine IL-11. Notably, FL-NI achieved a 117.8% increase in pulmonary drug delivery by noninvasive inhalation and a 71.5% increase in delivery specifically to fibroblast activation protein–positive myofibroblasts while reducing nonspecific immune cell and epithelial uptake by 29.8 and 55.8%, respectively. The accurate inhalation codelivery of nintedanib and siIL11 into myofibroblasts achieved synergistic effects, effectively enhanced myofibroblast deactivation, reduced pathological collagen deposition by 50.8%, and promoted epithelial tissue repair. FL-NI remodeled the aberrant immune microenvironment without inducing systemic toxicities. Therefore, this work demonstrated the notable potential for this pluripotent strategy for improving PF outcomes and its promising clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices Soochow University, Suzhou 215123, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
- School of Materials Science and Engineering, Tongji University, Shanghai 201804, China.
- Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Zhike Chen, Jian Yang, Qiang Zhang, Weibiao Zeng, Yi Liu, Wenxuan Hu, Linfu Chen, Jingjing Shen, Yu Miao, Zhisheng Xiao, Zhiqiang Wu, He Wang, Hui Shen, Cheng Ding, Qian Chen, Jun Zhao, Yang Yang
Zitieren
APA
Chen, Z., Yang, J., Zhang, Q., Zeng, W., Liu, Y., Hu, W., Chen, L., Shen, J., Miao, Y., Xiao, Z., Wu, Z., Wang, H., Shen, H., Ding, C., Chen, Q., Zhao, J., & Yang, Y. (2025). Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis. Science Advances, 11(18). https://doi.org/10.1126/sciadv.adv9571
Vancouver
Chen Z, Yang J, Zhang Q, Zeng W, Liu Y, Hu W, et al. Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis. Science Advances. 2025;11(18). doi:10.1126/sciadv.adv9571
BibTeX
@article{Chen2025,
author = {Chen, Zhike and Yang, Jian and Zhang, Qiang and Zeng, Weibiao and Liu, Yi and Hu, Wenxuan and Chen, Linfu and Shen, Jingjing and Miao, Yu and Xiao, Zhisheng and Wu, Zhiqiang and Wang, He and Shen, Hui and Ding, Cheng and Chen, Qian and Zhao, Jun and Yang, Yang},
title = {Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {18},
doi = {10.1126/sciadv.adv9571}
}
EUVIMED